| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
Not extensively characterized; as a quinone compound, it may interact with various cellular targets including NF-kappaB, STAT3, and Nrf2 pathways, similar to other tanshinones. Its pigment properties suggest potential interactions with proteins and nucleic acids.
|
|---|---|
| ln Vitro |
In vitro activity data are limited. As a diterpenoid quinone, nortanshinone likely exhibits antioxidant, anti-inflammatory, and cytotoxic activities similar to other tanshinones. It may inhibit cell proliferation in cancer cell lines through induction of apoptosis and cell cycle arrest, though specific IC50 values are not well documented.
|
| ln Vivo |
In vivo activity data are not well characterized. Based on related tanshinones, nortanshinone may exhibit cardiovascular protective effects, anti-inflammatory activity, and potential antitumor effects in animal models. However, specific in vivo studies for this compound are limited in the literature.
|
| Enzyme Assay |
No specific cell-free assay protocols are available for nortanshinone. General assays for quinone compounds include: DPPH radical scavenging assay for antioxidant activity (0.1-100 uM compound in methanol, incubated with DPPH for 30 min, absorbance at 517 nm), and enzyme inhibition assays such as COX-2 or LOX inhibition using colorimetric or fluorometric detection.
|
| Cell Assay |
Cytotoxicity assay: Cancer cell lines (e.g., HeLa, MCF-7, HepG2) are seeded in 96-well plates and treated with nortanshinone (0.1-100 uM) for 24-72 hours. Cell viability is measured by MTT or CCK-8 assay, with absorbance read at 570 nm or 450 nm. IC50 values are calculated from dose-response curves.
|
| Animal Protocol |
No specific animal models have been reported for nortanshinone. Based on related tanshinones, mouse models of inflammation (carrageenan-induced paw edema) or cancer xenograft models could be used. Dosing (e.g., 10-50 mg/kg i.p. or p.o.) would be administered daily for 7-14 days with endpoint measurements of tumor volume or inflammatory markers.
|
| ADME/Pharmacokinetics |
No pharmacokinetic data are available for nortanshinone. As a lipophilic quinone (logP ~3-4), it likely has moderate oral absorption, extensive protein binding, and hepatic metabolism via CYP450 enzymes. Half-life and bioavailability are not reported in the literature.
|
| Toxicity/Toxicokinetics |
No toxicity data are available for nortanshinone. As a natural quinone, it may exhibit mild cytotoxicity at high concentrations. No acute or chronic toxicity studies have been reported. The compound is generally considered safe for research use at micromolar concentrations.
|
| References | |
| Additional Infomation |
Reports indicate that tanshinone exists in tanshinone, tanshinone prorocentrum, and tanshinone yunnanensis, and relevant data are available for reference.
Nortanshinone is a research compound, not a drug. It is a pigment isolated from Salvia miltiorrhiza (Danshen) and serves as a reference standard for natural product chemistry and traditional medicine research. Its structure is related to tanshinones, which are known for cardiovascular and anti-inflammatory activities. |
| Molecular Formula |
C17H12O4
|
|---|---|
| Molecular Weight |
280.2748
|
| Exact Mass |
280.073
|
| CAS # |
97399-70-7
|
| PubChem CID |
10062187
|
| Appearance |
Brown to reddish brown solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
532.2±49.0 °C at 760 mmHg
|
| Flash Point |
264.7±22.5 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.641
|
| LogP |
3.15
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
21
|
| Complexity |
511
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=COC2=C1C(=O)C(=O)C3=C2C=CC4=C3CCCC4=O
|
| InChi Key |
YUFZXVOYNSJPSJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H12O4/c1-8-7-21-17-11-6-5-9-10(3-2-4-12(9)18)14(11)16(20)15(19)13(8)17/h5-7H,2-4H2,1H3
|
| Chemical Name |
1-methyl-8,9-dihydro-7H-naphtho[1,2-g][1]benzofuran-6,10,11-trione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5680 mL | 17.8399 mL | 35.6799 mL | |
| 5 mM | 0.7136 mL | 3.5680 mL | 7.1360 mL | |
| 10 mM | 0.3568 mL | 1.7840 mL | 3.5680 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
